Shuhei Yajima
Hamamatsu University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shuhei Yajima.
Pediatrics International | 2003
Teruaki Hongo; Chieko Watanabe; Shuichi Okada; Noriko Inoue; Shuhei Yajima; Yuji Fujii; Takehiko Ohzeki
Abstract Background : In an effort to improve the quality of life of children with cancer, this study analyzes the signs and symptoms at the end of life in such children. It is hoped that these data will contribute to the development of appropriate programs to address the challenges faced by these children.
Pediatrics International | 2003
Yuji Fujii; Chieko Watanabe; Shuichi Okada; Noriko Inoue; Akira Endoh; Shuhei Yajima; Teruaki Hongo; Takehiko Ohzeki; Eriko Suzuki
Abstract Background : With the aim of improving the quality of life of children with cancer, this study presents an analysis of one hospitals experience with terminal care.
Bone Marrow Transplantation | 2001
Chieko Watanabe; Shuhei Yajima; T Taguchi; K Toya; Yuji Fujii; Teruaki Hongo; Takehiko Ohzeki
We describe the successful treatment of a 20-year-old patient with chronic granulomatous disease (CGD), by unrelated bone marrow transplantation (UBMT). The patient is relatively old compared to other CGD patients treated with BMT. He had had repeated serious infections from early childhood and was diagnosed as CGD, gp91-phox deficiency. Prolonged antibiotic-resistant pneumonitis worsened when the patient was 18 years old. In addition, he suffered Aspergillus osteomyelitis and acute renal failure due to amphotericin B. He received 94 granulocyte transfusions from 94 adult donors and the infections gradually improved. In September 1998, at 20 years of age, he underwent UBMT from an HLA 6 antigen-matched male donor, with CY and TBI conditioning. He received MTX and CsA as prophylaxis against GVHD. No serious complications occurred and rapid engraftment was achieved. Acute GVHD (grade 2, at day 19) and chronic GVHD (limited, at day 192) occurred. However, both were easily controlled. The patient is alive and well with no late rejection 26 months after UBMT. Bone Marrow Transplantation (2001) 28, 83–87.
International Journal of Hematology | 2002
Teruaki Hongo; Shuichi Okada; Noriko Inoue; Sayuri Yamada; Shuhei Yajima; Chieko Watanabe; Yuji Fujii; Yasuo Horikoshi
The development of effective chemotherapy is imperative for children with Philadelphia chromosome—positive (Ph) acute lymphoblastic leukemia (ALL) because of the poor prognosis of this condition. Initial cellular drug resistance is thought to be an important cause of induction failure and early relapse.We carried out in vitro tests using a methyl-thiazol-tetrazolium assay on bone marrow samples from 274 children with newly diagnosed ALL. Sixteen children (5.8%) had Ph-positive results of cytogenetic analysis. We examined in vitro drug resistance to 14 agents and found that leukemic cells in Ph ALL were significantly more resistant than were cells in non-Ph ALL to melphalan, bleomycin, etoposide, mitoxantrone, L-asparaginase, and vinblastine. With the prednisolone, L-asparaginase, and vincristine (PAV) combination of drugs, 10 of the 16 Ph patients with ALL (62.5%) showed relative resistance (RR) (sensitivity to only 1 or to none of the 3 drugs) at initiation of treatment.These 10 patients experienced significantly poorer event-free survival (EFS) than did the 6 patients with supersensitivity (SS) (defined as sensitivity to all 3 or to 2 of the 3 drugs,P = .019). Leukemic cells from RR patients were found to be multiresistant to 12 drugs with 2.0- to 58.4-fold RR compared with cells from SS patients. This PAV sensitivity delineates initially sensitive and resistant groups. Of these, the SS subgroup of Ph ALL patients may be curable with chemotherapy and stem cell transplantation. For EFS improvement in the RR group, it may be necessary to use a new chemotherapy approach from initiation.
Pediatrics International | 1995
Teruaki Hongo; Yuji Fujii; Shuhei Yajima; Noriko Ogawa; Yasuko Kinjo
In Japan terminal medicine for children dying from cancer has not yet been developed nor has a support system for home terminal care and bereaved families been established. We have analyzed our own experiences in these areas and researched the possibilities of establishing support systems.
Pediatrics International | 1991
Yuji Fujii; Teruaki Hongo; Hiroyuki Masui; Takako Chiba; Nobuko Furukawa; Hiroaki Nakajima; Kaoru Nasuda; Shuhei Yajima; Yasuo Horikoshi; Yoshio Igarashi
Angiotensin‐induced hypertension chemotherapy (IHC) was investigated in six children with the following advanced malignancies: hepatocellular carcinoma, extraskeletal Ewings sarcoma, sacrococcygeal malignant teratoma, small round cell tumor of the chest wall, hepatoblastoma and osteogenic sarcoma. Partial response was achieved in three of these patients, two showed no change, and in one IHC was used as adjuvant chemotherapy. The side effects of IHC were minimal and tolerable. Angiotensin‐IHC may provide a new approach to pediatric cancer chemotherapy.
Blood | 1997
Teruaki Hongo; Shuhei Yajima; Minoru Sakurai; Yasuo Horikoshi; Ryoji Hanada
International Journal of Hematology | 1999
Teruaki Hongo; Sayuri Yamada; Shuhei Yajima; Chieko Watanabe; Yuji Fujii; Kawasaki H; Makoto Yazaki; Ryoji Hanada; Yasuo Horikoshi
Hepato-gastroenterology | 2003
Yoshihiro Yokoi; Shohachi Suzuki; Satoshi Baba; Takehiko Ohzeki; Shuhei Yajima; Shuichi Okada; Takuya Okumura; Hiroyuki Konno; Satoshi Nakamura
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association) | 2000
Kiyotaka Kurachi; Shohachi Suzuki; Hiroyuki Konno; Shuhei Yajima; Takehiko Ohzeki; Satoshi Nakamura